

Press release from Emotra AB (publ)

Göteborg, June 27, 2017

EMOTRA AB: Flagging notification

As a result of the recent rights issue in Emotra AB (publ) (“Emotra”), the total equity share owned by board member Lars-Håkan Thorell and his family has shrunk to below 10 per cent.

Lars-Håkan Thorell is Emotra’s Chief of Research and has been a member of the Company’s Board of Directors since June, 2006. Thorell is the inventor of EDOR®, Emotra’s measuring method and product system. As a consequence of the recent rights issue in Emotra, encompassing a total of 4,184,399 new shares, the percentage of equity and votes controlled by Lars-Håkan Thorell and his family member Elizabeth Kaminski has diminished from about 13.60 per cent to approximately 9.40 per cent. Together, Lars-Håkan Thorell and Elizabeth Kaminski own 1,290,976 shares in Emotra.

For further information about Emotra, please contact:

Claes Holmberg, CEO

Telephone: +46 708 25 45 47

E-mail: claes@emotra.se

This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on June 27, 2017 under the above contact’s supervision.

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company’s method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient’s response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden

Tel: +46 708 25 45 47, www.emotra.se